Nelson J Nieves

Array ( [id] => 13490249 [patent_doc_number] => 20180296667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/021065 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21817 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16021065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444739 [patent_doc_number] => 20180273912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => INFLUENZA VIRUS AND TYPE 1 DIABETES [patent_app_type] => utility [patent_app_number] => 15/862773 [patent_app_country] => US [patent_app_date] => 2018-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15862773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16213970 [patent_doc_number] => 10729762 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto [patent_app_type] => utility [patent_app_number] => 15/848706 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 11558 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15848706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12814177 [patent_doc_number] => 20180163229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS CONTAINING A DESIGNED ANKYRIN REPEAT PROTEIN (DARPIN) OR FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 15/838222 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15838222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12126263 [patent_doc_number] => 20180009850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'INFLUENZA TREATMENT AND/OR CHARACTERIZATION, HUMAN-ADAPTED HA POLYPEPTIDES; VACCINES' [patent_app_type] => utility [patent_app_number] => 15/648540 [patent_app_country] => US [patent_app_date] => 2017-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 38735 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15648540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702651 [patent_doc_number] => 20170362280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => HIV VACCINE FORMULATION [patent_app_type] => utility [patent_app_number] => 15/623684 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486828 [patent_doc_number] => 09993547 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines [patent_app_type] => utility [patent_app_number] => 15/596084 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14125 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969886 [patent_doc_number] => 20170274040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'TREATMENT OF CANCERS WITH IMMUNOSTIMULATORY HIV TAT DERIVATIVE POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/587262 [patent_app_country] => US [patent_app_date] => 2017-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 14605 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15587262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14147669 [patent_doc_number] => 10254204 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Membrane-assisted purification [patent_app_type] => utility [patent_app_number] => 15/586132 [patent_app_country] => US [patent_app_date] => 2017-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 39 [patent_no_of_words] => 14453 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15586132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14085713 [patent_doc_number] => 10238736 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-26 [patent_title] => Adjuvant compositions [patent_app_type] => utility [patent_app_number] => 15/494920 [patent_app_country] => US [patent_app_date] => 2017-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 30948 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15494920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11836311 [patent_doc_number] => 20170218030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE' [patent_app_type] => utility [patent_app_number] => 15/488815 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 34137 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15488815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14911063 [patent_doc_number] => 10426831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-01 [patent_title] => Antiviral vaccines with improved cellular immunogenicity [patent_app_type] => utility [patent_app_number] => 15/489220 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 41 [patent_no_of_words] => 16975 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326597 [patent_doc_number] => 10294302 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Therapeutic method and medicament for HTLV-1 associated myelopathy [patent_app_type] => utility [patent_app_number] => 15/475367 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 34 [patent_no_of_words] => 13090 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15475367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743973 [patent_doc_number] => 20170198046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'COMPOSITIONS CAPABLE OF SPECIFICALLY BINDING PARTICULAR HUMAN ANTIGEN PRESENTING MOLECULE/ ANTIGEN COMPLEXES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/466921 [patent_app_country] => US [patent_app_date] => 2017-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 48574 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15466921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13013923 [patent_doc_number] => 10030069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-24 [patent_title] => High affinity human antibodies to human cytomegalovirus (CMV) gB protein [patent_app_type] => utility [patent_app_number] => 15/464165 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5156 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15464165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326555 [patent_doc_number] => 10294281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => High-transduction-efficiency rAAV vectors, compositions, and methods of use [patent_app_type] => utility [patent_app_number] => 15/444235 [patent_app_country] => US [patent_app_date] => 2017-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 79 [patent_no_of_words] => 22562 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15444235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11670419 [patent_doc_number] => 20170159139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'COMPOSITIONS AND METHODS FOR DETERMINING WHETHER A SUBJECT WOULD BENEFIT FROM CO-RECEPTOR INHIBITOR THERAPY' [patent_app_type] => utility [patent_app_number] => 15/436065 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14839 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15436065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11671525 [patent_doc_number] => 20170160246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'BIOMARKERS FOR ASSESSING HIV' [patent_app_type] => utility [patent_app_number] => 15/387932 [patent_app_country] => US [patent_app_date] => 2016-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 12296 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15387932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14423011 [patent_doc_number] => 10316295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Paramyxovirus virus-like particles as protein delivery vehicles [patent_app_type] => utility [patent_app_number] => 15/383324 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12947 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15383324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13854037 [patent_doc_number] => 10188725 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => Hybrid core feline vaccines [patent_app_type] => utility [patent_app_number] => 15/375398 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18207 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375398 [rel_patent_id] =>[rel_patent_doc_number] =>)